Spots Global Cancer Trial Database for Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

Study Description

Brief Summary: Subjects are asked to take part in a clinical research study that tests Eribulin, a new drug. Eribulin is an investigational (experimental) anti-cancer agent that has not been approved by the Food and Drug Administration (FDA) for use in patients with brain metastases. Eribulin is FDA approved for use in patients with metastatic breast cancer but the effect it may or may not have on brain metastases has not been studied.

Detailed Description: Primary Objectives: To determine the 3-month central nervous system (CNS)-progression free survival (PFS) for patients with metastatic breast cancer with brain metastases treated with eribulin mesylate. Secondary Objective(s): 1. Estimate CNS complete and partial response rates (CR and PR) and duration of CNS response in this patient population. 2 Evaluate toxicity in patients with breast cancer with brain metastases treated with eribulin mesylate. 3 Estimate clinical benefit rate (CBR) at 3 months in breast cancer patients with brain metastases treated with eribulin mesylate. (CBR is the sum of CR, PR and stable disease at 3 months). 4 To estimate systemic disease (extra cranial) response rate and duration of systemic response in this patient population. 5 Overall survival in this patient population. Design: This is a phase II study that will require patients to evaluate the primary objective (CNS PFS at 3 months). Study patients will have a baseline brain MRI and a second MRI at 12 weeks to evaluate disease.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial